Morgan Stanley has revised its price target for Idexx Laboratories (IDXX, Financial), setting a new target of $548, a slight reduction from the previous target of $559. Despite this adjustment, the firm continues to assign an Overweight rating to the company's shares.
The focus within the Healthcare Services and Technology sector will remain on policy developments, which may affect companies to varying extents. Additionally, the focus will be on analyzing underlying utilization trends across various segments, including managed care organizations, distributors, providers, labs, as well as the animal and dental sectors, as they transition into the first quarter.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for IDEXX Laboratories Inc (IDXX, Financial) is $508.04 with a high estimate of $566.00 and a low estimate of $389.50. The average target implies an upside of 25.55% from the current price of $404.65. More detailed estimate data can be found on the IDEXX Laboratories Inc (IDXX) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, IDEXX Laboratories Inc's (IDXX, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for IDEXX Laboratories Inc (IDXX, Financial) in one year is $567.98, suggesting a upside of 40.36% from the current price of $404.65. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the IDEXX Laboratories Inc (IDXX) Summary page.
